普莱柯：子公司获鸡新城疫等三联灭活疫苗新兽药注册证书

Core Viewpoint - The announcement indicates that the company's wholly-owned subsidiary, Luoyang Huizhong Biotechnology Co., Ltd., has received a new veterinary drug registration certificate for a trivalent inactivated vaccine targeting three chicken diseases, enhancing the company's product portfolio and competitiveness in the poultry vaccine market [1] Group 1 - The vaccine is designed to prevent three diseases: Newcastle disease, avian influenza (H9 subtype), and infectious bursal disease [1] - The registration certificate was issued by the Ministry of Agriculture and Rural Affairs on January 12, 2026, marking a significant regulatory milestone for the product [1] - The vaccine is classified as a Category III new veterinary drug, indicating its potential impact on animal health and the poultry industry [1] Group 2 - The product still requires approval for veterinary drug product registration before it can be marketed, indicating further steps in the regulatory process [1] - This development enriches the company's poultry vaccine offerings, which is expected to enhance its competitive edge in the market [1]